Pacific Biosciences of California Inc (NASDAQ:PACB) currently has a daily average trading volume of 10.67M but it saw 6788133 shares traded in last market. With a market cap of 339.55M USD, the company’s current market price of $1.14 came falling about -2.56 while comparing to the previous closing price of $1.17. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.72 and as low as $1.08. In the recent trading on the day, stock has struck highest price mark of $1.13 while lowest mark touched by it was $1.19.
Taking a look at 20-day trading activity of Pacific Biosciences of California Inc (PACB) gives us an average price of $1.2335, while its current price level is -58.09% below from 52-week high level whereas it is 5.56% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.3425 while that of 200 days or SMA-200 reads an average of $1.6837. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.29% during that period while stretching the period over a month that increases to 10.06%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.73 which implies that the stock is in neutral territory.
Over the week, PACB’s stock price is moving -5.00% down while it is -12.98% when we observe its performance for the past one month. Year-to-date it is -37.70% down and over the past year, the stock is showing a downside performance of -26.92%.
The company is expected to be releasing its next quarterly report on 2025-Feb-12, for which analysts forecasted an EPS of -0.19 while estimate for next year EPS is -0.71. In next quarter, company is expected to be making quarterly sales of $37.67M as analysts are expecting the sales for current fiscal year at $160.2M and seeing the company making $195.87M in sales next year. Moreover, analysts are in estimates of $36.9M for current-quarter revenue.
Currently, Pacific Biosciences of California Inc’s total number of outstanding shares is 294.42M with 9.18% of that held by the insiders while 73.21% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -26.40% and return on equity (ROE) at -51.11%. Stock’s beta reads 2.15. Stock has a price to book (P/B) ratio of 0.66 while price to sale or P/S ratio amounts to 2.20. Its return on asset (ROA) is -20.53% on average.
